Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. on April 21, 2020. The report discloses the announcement of top-line data from the KALM-2 pivotal Phase 3 clinical trial for KORSUVA (difelikefalin) Injection, intended for hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory timelines.
Material Changes and Clinical Results
The primary material event is the successful completion of the KALM-2 trial, a 12-week, global, multicenter, randomized, double-blind, placebo-controlled study involving 473 patients. Key results include:
- Primary Endpoint: 54% of patients on KORSUVA achieved a three-point or greater improvement in itching intensity (WI-NRS) at week 12, compared to 42% on placebo (p=0.02).
- Key Secondary Endpoint: 41% of patients on KORSUVA achieved a four-point or greater improvement, compared to 28% on placebo (p=0.01).
- Quality of Life: Numerical improvements were observed in Skindex-10 (12%) and 5-D Itch scores (29%), though these did not meet statistical significance.
- Safety Profile: The drug was generally well-tolerated. The most common adverse events (>5%) included diarrhea, falls, vomiting, nausea, and dizziness, with incidence rates similar to the placebo group.
Guidance, Outlook, and Risks
Management remains on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2020. Submission for marketing approval to the European Medicines Agency (EMA) is anticipated shortly thereafter. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks described in the company's Form 10-K.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the primary and secondary endpoints in the full data set.
- Confirm the specific timeline for the FDA NDA submission in the second half of 2020.
- Review the detailed safety data regarding adverse events, particularly falls and gastrointestinal issues, in the full clinical report.
- Assess the company's cash runway to support operations through the regulatory review process, as no financial data is provided in this filing.